Provided are processes of determining die immimogenicity of a rabies virus vaccine preparation that for the first tiine correlates well with in vivo results. The methods capitalize on an ECL assay for RABV G protein that is sensitive, reproducible, and can be used to quickly assess characteristics of new vaccine preparations.